<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627598</url>
  </required_header>
  <id_info>
    <org_study_id>140284</org_study_id>
    <nct_id>NCT03627598</nct_id>
  </id_info>
  <brief_title>High Flow Oxygen and Non Invasive Ventilation for Hypercapnic Respiratory Failure</brief_title>
  <official_title>High Flow Nasal Oxygen in Addition to Non Invasive Ventilation During Hypercapnic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Mahdia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Mahdia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study evaluates high flow oxygen therapy in addition to non invasive ventilation (NIV)
      to treat hypercapnic respiratory failure. Between sessions of NIV, half of participants will
      have high flow nasal cannula while the others will have standard low flow oxygen therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High Flow Nasal Cannula (HFNC) is a new way of oxygen therapy that has gained interest in the
      management of patients with acute respiratory failure. It allows reaching a high flow air up
      to 60 liters / min via a nasal cannula with a humidification and warming of the air
      administered. It has a number of physiological effects such as wash out of anatomical dead
      space, generation of a small PEEP and high inspired fraction of oxygen which enhances
      compliance and reduces inspiratory efforts.

      NIV is the corner stone in the treatment of severe COPD exacerbation. Nevertheless, prolonged
      application of the facial mask expose to local complications and intolerance which can be a
      cause of failure, so reducing the duration of exposure to this procedure is important.

      The role of HFNC in supplementing NIV effect during hypercapnic respiratory failure has not
      been assessed. Much of the data available on HFNC are about hypoxemic respiratory failure.

      Because of its physiological effects, it can be hypothesized that HFNC in addition to NIV can
      shorten its duration by facilitating carbon dioxide clearance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of NIV</measure>
    <time_frame>28 days</time_frame>
    <description>number of days patients received NIV, and for patients with home NIV: it is the number of days spent to achieve the usual daily NIV hours with clinical and gasometric stability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to obtain NIV withdrawal criteria</measure>
    <time_frame>28 days</time_frame>
    <description>the day patients do not have signs of acute respiratory failure and no respiratory acidosis (pH &lt;7.36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIV failure</measure>
    <time_frame>28 days</time_frame>
    <description>need for intubation or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>number of days spent in the ICU for this episode of exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>death in the ICU during the recorded episode</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions</description>
    <arm_group_label>HFNC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard</intervention_name>
    <description>patients will receive low flow oxygen therapy at 1 to 4 liters per minute</description>
    <arm_group_label>standard group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged more than 18 years with a diagnosis of acute-on-chronic respiratory
             failure and respiratory acidosis requiring NIV.

        Exclusion Criteria:

          -  Patient included in another study

          -  Patients intubated at ICU admission or within 12 hours

          -  Contraindication to NIV including: pneumothorax, Hemodynamic instability, GCS less
             than 12, facial malformation

          -  Asthma

          -  A do not intubate order

          -  Neuromuscular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nejla Tilouche, MD</last_name>
    <phone>0021623277911</phone>
    <email>tilouche.nejla@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>souheil elatrous, MD</last_name>
    <phone>0021698403053</phone>
    <email>souheilatrous@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intensive Care Unit</name>
      <address>
        <city>Mahdia</city>
        <zip>5100</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nejla Tilouche, MD</last_name>
      <phone>0021623277911</phone>
      <email>tilouche.nejla@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>souheil Elatrous, MD</last_name>
      <phone>0021698403053</phone>
      <email>souheilatrous@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <reference>
    <citation>Lepere V, Messika J, La Combe B, Ricard JD. High-flow nasal cannula oxygen supply as treatment in hypercapnic respiratory failure. Am J Emerg Med. 2016 Sep;34(9):1914.e1-2. doi: 10.1016/j.ajem.2016.02.020. Epub 2016 Feb 12.</citation>
    <PMID>26947372</PMID>
  </reference>
  <results_reference>
    <citation>Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.</citation>
    <PMID>25981908</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Mahdia</investigator_affiliation>
    <investigator_full_name>Nejla Tilouche</investigator_full_name>
    <investigator_title>medecine doctor</investigator_title>
  </responsible_party>
  <keyword>high flow oxygen</keyword>
  <keyword>non invasive ventilation</keyword>
  <keyword>hypercapnic respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

